Tumor suppressors control ULBP2, an innate surface ligand of the lymphocyte immune receptor NKG2D

OncoImmunology

Volumn 1, Issue 4, 2012, Pages 535-536

  Heinemann, Anja ^a   Paschen, Annette ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Cancer; miR 34; NKG2D ligand; P53; ULBP2

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 34; MICRORNA 34A; MICRORNA 34C; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN P53; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; ULBP2 PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADAPTIVE IMMUNITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; CELL CYCLE ARREST; CYTOTOXIC LYMPHOCYTE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; INNATE IMMUNITY; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; TUMOR ESCAPE; TUMOR GENE; TUMOR SUPPRESSOR GENE; ULBP2 GENE; UPREGULATION;

EID: 84872558718     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.19406     Document Type: Article

References (10)

1. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010; 235:267-85;
2. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 436: 1186-90; http://dx.doi.org/10.1038/nature03884
3. Heinemann A, Zhao F, Pechlivanis S, Eberle J, Steinle A, Diederichs S, et al. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress- induced ligand of the natural killer cell receptor NKG2D. Cancer Res 2012; 72:460-71; http://dx.doi.org/10.1158/0008-5472.CAN-11-1977
4. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010; 17:193-9; http://dx.doi.org/10.1038/cdd.2009.56
5. Agostini M, Tucci P, Killick R, Candi E, Sayan BS, Rivetti di Val Cervo P, et al. Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proc Natl Acad Sci U S A 2011; 108:21093-8; http://dx.doi.org/10.1073/pnas.1112061109
6. Rinaldo C, Prodosmo A, Siepi F, Moncada A, Sacchi A, Selivanova G, et al. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA. Cancer Res 2009; 69:6241-8; http://dx.doi.org/10.1158/0008-5472.CAN-09-0337
7. Textor S, Fiegler N, Arnold A, Porgador A, Hofmann TG, Cerwenka A. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res 2011; 71:5998-6009; http://dx.doi.org/10.1158/0008-5472.CAN-10-3211
8. Li H, Lakshmikanth T, Garofalo C, Enge M, Spinnler C, Anichini A, et al. Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2. Cell Cycle 2011; 10:3346-58; http://dx.doi.org/10.4161/cc.10.19.17630
9. Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen XD, et al. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 2009; 15:5208-15; http://dx.doi.org/10.1158/1078-0432.CCR-09-0886
10. Schwinn N, Vokhminova D, Sucker A, Textor S, Striegel S, Moll I, et al. Interferon-gamma downregulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int J Cancer 2009; 124:1594-604; http://dx.doi.org/10.1002/ijc.24098